

Serial No.: 08/450,437  
Group Art Unit No.: 1711

**IN THE CLAIMS:**

Please amend the claims, as follows:

B2  
15. (Amended) A method for the treatment and/or prophylaxis of pulmonary disorders [(asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough)], skin disorders and itch [(for example, atopic dermatitis and cutaneous wheal and flare)], neurogenic inflammation and CNS disorders [(Parkinson's disease, movement disorders, anxiety)], convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim 1.

16. (Amended) A method for the treatment and/or prophylaxis of convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of an NK<sub>3</sub> receptor antagonist.

B3  
28  
22. (Amended) A method for the treatment and/or prophylaxis of pulmonary disorders [(asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough)], skin disorders and itch [(for example, atopic dermatitis and cutaneous wheal and flare)], neurogenic inflammation and CNS disorders [(Parkinson's disease, movement disorders, anxiety)], convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, pharmaceutically acceptable, and non-toxic amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim 17.

B4  
42  
25. (Amended) A method for the treatment and/or prophylaxis of pulmonary disorders [(asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough)], skin disorders and itch [(for example, atopic dermatitis and cutaneous wheal and flare)], neurogenic inflammation and CNS disorders [(Parkinson's disease, movement disorders, anxiety)], convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic

101

Serial No.: 08/450,437

Group Art Unit No.: 1711

rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, pharmaceutically acceptable, and non-toxic amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim <sup>40</sup>23.

(Please add new claims 26-58, as follows:)

- 12-26. The method according to claim 15, wherein the pulmonary disorder is asthma.
- 13-27. The method according to claim 15, wherein the pulmonary disorder is chronic obstructive pulmonary disease.
- 14-28. The method according to claim 15, wherein the pulmonary disorder is airway hyperreactivity.
- 15-29. The method according to claim 15, wherein the pulmonary disorder is cough.
- 16-30. The method according to claim 15, wherein the skin disorder is atopic dermatitis.
- 17-31. The method according to claim 15, wherein the skin disorder is cutaneous wheal and flare.
- 18-32. The method according to claim 15, wherein the CNS disorder is Parkinson's disease.
- 19-33. The method according to claim 15, wherein the CNS disorder comprises movement disorders.
- 20-34. The method according to claim 15, wherein the CNS disorder is anxiety.
- 21-35. The method according to claim 15, wherein the eating disorder is food intake inhibition.
- 22-36. The method according to claim 15, wherein the neurodegenerative disorder is Alzheimer's disease.
- 29-37. The method according to claim 22, wherein the pulmonary disorder is asthma.
- 30-38. The method according to claim 22, wherein the pulmonary disorder is chronic obstructive pulmonary disease.
- 31-39. The method according to claim 22, wherein the pulmonary disorder is airway hyperreactivity.
- 32-40. The method according to claim 22, wherein the pulmonary disorder is cough.
- 33-41. The method according to claim 22, wherein the skin disorder is atopic dermatitis.
- 34-42. The method according to claim 22, wherein the skin disorder is cutaneous wheal and flare.
- 35-43. The method according to claim 22, wherein the CNS disorder is Parkinson's disease.